** Curriculum Vitae**

**\*\*\*\*\*\***

**Dr. Amol Patel, MBBS, MD, DM**

**PERSONAL DETAILS**

Name : Dr. Amol Patel

Date of Birth : Mar 6th 1978

Office Address : Department of Medicine,

 Indian Naval Hospital Ship,

 Mumbai 400005

Address : 12, Bhagirathi, Colaba,

 Mumbai 400005

Email : dr.amolpatel@gmail.com,

 dr.amolpatel@hotmail.com

Phone Number : +919999856335

**CURRENT DESIGNATION**

**Senior Advisor (Medicine) & Medical Oncologist**

**Associate Professor of Medicine**

**Department of Medicine,**

**Indian Naval Hospital Ship,**

**Mumbai 400005.**

Former CO-Supervisor (**affiliated to Delhi University**)

(Medicine and Medical & Hemato-Oncology)

Department of Medical Oncology

Malignant Diseases Treatment Centre

Army Hospital Research & Referral

New Delhi 110010

**Associate Editor**

Pharmacoeconomics, Indian Journal of Medical & Pediatric Oncology (IJMPO)

Official Journal of Indian Society of Medical & Pediatric Oncology (ISMPO)

**EDUCATIONAL QUALIFICATION**

* **M.B.B.S.** (Bachelor of Medicine and Bachelor of Surgery) 1996-2001

Rural Medical College, Pune University, Maharashtra, India.

* **MD** Internal Medicine, 2006-2009

Department of Internal Medicine, Armed Forces Medical College, Pune 411040, Maharashtra University of Medical Sciences.

* **DM** Medical Oncology 2014-2017

Department of Medical Oncology, Dr BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi – 110029

**PUBLICATIONS**

**Original articles**

1. **Patel A**, Sharma MC, Bakhshi S. Demographic Challenges of Pediatric NHL: A Report on 280 Patients. Indian J Pediatr. 2017 Dec 14.
2. **Patel A**, Sharma MC, Mallick S, Patel M, Bakhshi S. Poor performance status, urban residence and female sex predict inferior survival in pediatric advanced stage mature B-NHL in an Indian tertiary care center. Pediatr Hematol Oncol. 2018 Feb 1;1–10.
3. **Patel A**, Tiwari A, Biswas B, Sharma MC, Vishnubhatla S, Bakhshi S. Clinical Predictors and Prognostic Model for Pediatric Lymphoblastic Lymphoma treated with uniform BFM90 protocol: a single center experience of 65 patients from Asia. Clin Lymphoma Myeloma Leuk. 2019 Feb 7.
4. **Patel A**, Sharma MC, Bakhshi S. Outcome of Early Stage Pediatric Non-Lymphoblastic Non-Hodgkin Lymphoma. Indian J Pediatr. 2018 Feb 8.
5. **Patel A**, Tannock IF, Srivastava P, Biswas B, Gupta VG, Batra A, et al. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets. JCO Glob Oncol. 2020 Mar 1 ;( 6):382–6.
6. **Patel A**, Batra U, Prasad KT, Dabkara D, Ghosh J, Sharma M, et al. Real-world experience of treatment and outcome in ALK-rearranged metastatic non-small cell lung cancer: A multicenter study from India. Curr Probl Cancer. 2020 Mar 17; 100571.
7. **Patel A,** Pushpam D, Sharma M, Thulkar S, Bakhshi S. Predictors of Outcome in Pediatric Anaplastic Large Cell Lymphoma. INDIAN Pediatr. 2020; 57:4.
8. **Patel A,** Soneji D, Singh HP, Kumar M, Bandyopadhyay A, Mathur A, et al. Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective Study. South Asian J Cancer. 2020 Jun; 9(2):74–9.
9. **Patel A**, Shankaran R, Singh HP, Bhatnagar S, Dash SC, Mukherjee P, et al. Cancer trends and burden among Armed Forces personnel, veterans and their families: Cancer registry data analysis from tertiary care hospital. Med J Armed Forces India [Internet]. 2021 Apr 12[cited 2021Apr12]; Available from: https://www.sciencedirect.com/science/article/pii/S0377123720301854
10. **Patel A**, Akhade A. Pembrolizumab Weight-Based Dosing: Conviction and Lacunae in Adopting a Cost- Saving Approach—A Survey Report. Indian J Med Paediatr Oncol. :6.
11. Nair R, Kaushik MR, Kishore K, Singh HP, Vardhan V, Suresh P, **Patel A** et al. COVID-19, Cancer, and Congregation: An Observational Study from a Tertiary Care Hospital in New Delhi. Indian J Med Paediatr Oncol. 2021 Feb; 42(1):6–10.
12. Manali Patel, Raja Pramanik, **Amol Patel,** Personal Protective Equipment use is associated with physical and neurological dysfunction among health care workers - Survey Report during the Covid-19 Pandemic. Journal of the Association of Physicians of India, Vol. 69, 147, June 2021.
13. **Patel A**, Gupta VG, Guleria B, Das CK, Mehta P, Ramegowda KM. Real-World Breast Cancer Patient Follow-Up Practices by Medical Oncologists in India—A Survey Report. South Asian J Cancer [Internet]. 2022 Feb 5 [cited 2022 Feb 24]; Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1739187.
14. Kumar L, Gogi R, **Patel A**, Mookerjee A, Sahoo RK, Malik PS, et al. Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome. Bone Marrow Transplant. 2017 Oct; 52(10):1473–5.
15. Bandyopadhyay A, Talwar R, **Patel A**, Jaiswal P. The modifications in surgical technique and its impact on short term morbidity in modified radical mastectomy: a tertiary care hospital experience. Int Surg J. 2019 Nov 26; 6(12):4354–9.
16. Sood AK, Manrai M, Thareja S, Shukla R, **Patel A**. Epidemiology of hepatitis C virus infection in a tertiary care hospital. Med J Armed Forces India. 2019 Dec.http://www.sciencedirect.com/science/article/pii/S0377123719300942.
17. Kumar M, Kumar K, Singh HP, Nair S, **Patel A**, Kumar A, et al. Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer. South Asian J Cancer. 2020 Jun; 9(2):109–14.
18. Shivarudraiah SM, Viswanath S, Pandalanghat S, Soneji D, Kumar M, **Patel A**, et al. Adult Soft Tissue Sarcoma: A Prospective Observational Real-World Data. Indian J Med Paediatr Oncol. 2021 Aug; 42(4):339–45.
19. Guleria B, Viswanath S, Soneji D, Kapoor R, Guleria P, Suresh P, **Patel A** et al. Cancer in the Adolescent and Young Adults (AYA) and Children: A Comprehensive Analysis of the Epidemiology and Psychosocial Morbidity in the Indian Population. South Asian J Cancer [Internet]. 2021 Dec 31 [cited 2022 Jan 18]; Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1735482
20. **Patel A**, Pathak A, Sarin A, Shelly D, Ranjan R, Singh A, et al. Phase 1/2 Study of the Timing and Efficacy of 3 mg Peg-GCSF in Neo/Adjuvant Dose Dense Breast Cancer Treatment Protocols. South Asian J Cancer [Internet]. 2023 Aug 11 [cited 2023 Aug 22]; Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1757599.
21. Pathak N, I AR, Kulkarni P, **Patel A**. A Survey on Unmet Need for Uniform Next-Generation Sequencing Reporting in India. Indian J Med Paediatr Oncol [Internet]. 2023 Jul 5 [cited 2023 Aug 22]; Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1770936.
22. M.R. Kaushik, Amul Kapoor, H.P. Singh, P. Suresh, **Amol Patel** et al. Real world experience on patterns of usage and toxicity profile of immunotherapy drugs in Indian patients: A prospective observational study; MJAFI, 2023 ahead of print, online.

**Editorial –**

1. **Patel A**, Goldstein DA, Tannock IF. Improving Access to Immunotherapy in Low and Middle-Income Countries. Ann Oncol [Internet]. 2022 Jan 12 [cited 2022 Jan 18];0(0). Available from: https://www.annalsofoncology.org/article/S0923-7534(22)00008-4/fulltext
2. Tannock IF, **Patel A**. Pharmacoeconomics. Indian J Med Paediatr Oncol. 2021 May;42(3):218–20.
3. Rohith KP, **Patel A**. The burden of cancer caregivers: Time to acknowledge and start caring for the carers. Cancer Res Stat Treat. 2022 Jan 4; 5(2):309.
4. **Patel A**, Hande V. Rising colorectal cancer in young adults: A warning for all! Let us adopt a healthy lifestyle and colorectal cancer screening. Indian J Cancer. 2022 Sep; 59(3):307.
5. Noronha V, Mehta P, Malik PS, **Patel A**. First-line immunotherapy in advanced non-small-cell lung cancer. Indian J Med Paediatr Oncol. 2019 Oct 1; 40(4):461.
6. Ghosh J, Batra A, **Patel A**, Mehta P. Trastuzumab Emtansine for Residual Invasive Human Epidermal Growth Receptor-2-Positive Breast Cancer. Indian J Med Paediatr Oncol. 2020 Jul; 41(5):652–3.

**Letters and Correspondence -**

1. **Patel A**, Gupta VG. Adjuvant therapy in resectable gastric cancer—the CRITICS trial. **Lancet Oncol**. 2018 Jul 1; 19(7): e328.
2. **Amol Patel** VGG. Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. **N Engl J Med.** 2018 Oct 25; 379(17):1683–5.
3. **Patel A**, Tilak T, Gupta V, Batra A, Mehta P, Parikh P, et al. Dynamics of sequencing of cyclin-dependent kinase inhibitors and cost expenditure analysis in the management of metastatic hormone-receptor positive, human epidermal growth factor 2-negative advanced breast cancer. Indian J Med Paediatr Oncol. 2019; 40(2):311–3.
4. **Patel A,** Shivashankara MS. Fulvestrant: Do not forget the history and opportunities for cost saving from real-world data. Cancer Res Stat Treat. 2020 Jan 7; 3(3):663.
5. Mehta P, Batra A, **Patel A.** Commentary on Oncotype Dx. - Indian J Med Paediatr Oncol. 40(3):434.
6. Noronha V, Mehta P, Malik PS, **Patel A**. First-line immunotherapy in advanced non-small-cell lung cancer. Indian J Med Paediatr Oncol. 2019 Jan 10; 40(4):461.
7. **Patel A**, Sirohi B. Nab-paclitaxel - Third-line chemotherapy in advanced gallbladder cancer. Indian J Med Res. 2020; 152(5):442.
8. Sirohi B, Shrikhande S, Gaikwad V, **Patel A,** Patkar S, Goel M, et al. Indian Council of Medical Research consensus document on hepatocellular carcinoma. Indian J Med Res. 2020; 152(5):468.
9. **Patel A**, Gupta VG, Biswas B, Ganguly S, Das CK, Batra A, et al. Reply to D. O’Reilly et al. JCO Glob Oncol. 2021 Apr 1 ;( 7):648–648.
10. **Patel A**, Gupta VG, Biswas B, Das CK, Batra A, Ganguly S, et al. Revisiting Fulvestrant Dosing in Uncertain Economic Times. JCO Glob Oncol. 2021 Jan 6 ;( 7):1–3.
11. **Patel A**, Prashar M. ERBB and FGFR2 pathway inhibition in biliary tract cancers – Dawn of a new beginning. Int J Mol Immuno Oncol. 2021 Sep 27; 6(3):132–5.
12. Purvish MP, Mehta P, **Patel A**. Letter to editor. Int J Mol Immuno Oncol. 2022 Jun 1; 7(2):58–60.

 **Case series and reports -**

1. **Amol Patel**, Dharmesh Soneji, Deepak Mulajker, Manali Patel. Exertional Heat Stroke - Golden hour is the Key to Success: A Report from Peripheral Military Hospital of Northern India. J Assoc Physicians India. 67(January 2019) ISSN 1521-0669.
2. Shivarudraiah SM, **Patel A**, Singh S. Acute severe gastroparesis (mega-stomach), an unusual complication of autologous stem cell transplant: A case report. Cancer Res Stat Treat. 2022 Sep; 5(3):584–7.

**Review articles -**

1. **Patel A**, Akhade A, Parikh P, Sharma A, Malhotra H, Prabhash K, et al. Pembrolizumab weight-based dosing – A call for policy change. Indian J Med Paediatr Oncol. 2022 Feb 21; s-0042-1742651.
2. Gupta P, Dutta U, Rana P, Singhal M, Gulati A, Kalra N, **Amol Patel** et al. Gallbladder reporting and data system **(GB-RADS**) for risk stratification of gallbladder wall thickening on ultrasonography: an international expert consensus. Abdom Radiol N Y. 2021 Dec 1;
3. **Patel A**, Soneji D, Parikh P, Manish Kumar. Biomarkers in immuno-oncology: A review article. Int J Mol Immuno Oncol. 2019 Aug; 4(2):41–9. DOI -10.25259/IJMIO-12-2019.

1. Batra A, **Patel A**, Gupta VG, Mehta P, TVSVGK Tilak, Biswas B et al. Oncotype DX: Where Does It Stand in India? J Glob Oncol. 2019 Jul 1 ;( 5):1–2.
2. Parikh PM, Bhosale B, Lokeshwar N, Kamath M, Kumar A, Gulia A, **Patel A** et al. Mediclaim insurance challenges and solutions – Doctors supporting patients: A Medic LAWgic initiative. Indian J Med Sci. 71: doi.org/10.25259/IJMS
3. Patel A, Patel M, Tshering P, Koyyala VPB, Ghadyalpatil N. Chewing Doma (Fermented Betel Nut): Culture versus Cancer? South Asian J Cancer [Internet]. 2023 Apr 10 [cited 2023 Apr 27]; Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1764216.
4. Gupta P, Dutta U, Rana P, Singhal M, Gulati A, Kalra N, et al. Gallbladder reporting and data system (GB-RADS) for risk stratification of gallbladder wall thickening on ultrasonography: an international expert consensus. Abdom Radiol N Y. 2021 Dec 1;
5. Tilak TVSVGK, **Patel A**, Kapoor A. Molecular basis and clinical application of targeted therapy in oncology. Med J Armed Forces India [Internet]. 2023 Feb 28 [cited 2023 Feb 28]; Available from: https://www.sciencedirect.com/science/article/pii/S037712372300014X.
6. Hingmire S, Tshomo U, Dendrup T, **Patel A**, Parikh P. Cervical Cancer HPV Vaccination and Bhutan. South Asian J Cancer. 2023 Jan;12(1):41–3.

 **Thesis project -**

1. The Effect of Baseline Serum Zinc Level on Overall Survival in Paediatric AML Patients -A prospective observational study.

 **Covid-19 publications -**

1. **Patel A,** Batra A, Mehta P, Sharma A, Sirohi B, Biswas B, et al. Gallbladder cancer: Adjuvant and palliative treatment during Covid-19 pandemic in India. Indian J Med Paediatr Oncol. 2020 Jan 4;41(2):132.
2. Batra A, Mehta P, **Patel A**, Bhethanabhotla S, Biswas B, Pramanik R, et al. Breast cancer treatment during the COVID-19 pandemic. Indian J Med Paediatr Oncol. 2020 Jan 4;41(2):135.
3. Srivastava P, Tilak TVSVGK, **Patel A**, Das CK, Biswas B, Mahindru S, et al. Advisory for cancer patients during the COVID pandemic. Cancer Res Stat Treat. 2020 Jan 4;3(5):145.
4. Mehta P, Parikh P, Aggarwal S, Batra A, **Patel A**, Kulkarni P, et al. Has India met this enemy before? From an eternal optimist’s perspective: SARS-CoV-2. Indian J Med Sci. 2020 Apr 30;72(1):8–12.
5. Parikh P, Mehta P, Bansal S, Aggarwal S, **Patel A**, Batra A, et al. Protecting health-care professionals and workers (other than COVID-19 management facilities) from contamination during COVID-19 pandemic (March 26, 2020 – India). Indian J Med Sci. 2020 Apr 30;72(1):3–4.
6. Ghosh J, Ganguly S, Biswas B, Dabkara D, Srivastava P, **Patel A**, et al. Systemic treatment of gastro esophageal cancer during SARS-CoV2. Indian J Med Paediatr Oncol. 2020 Jan 4; 41(2):141.
7. Biswas B, Ganguly S, Dabkara D, Ghosh J, Srivastava P, Mehta P, **Patel A**, et al. How we treat lung cancer during SARS-Cov-2 (COVID-19) pandemic in India? Indian J Med Paediatr Oncol. 2020 Jan 4; 41(2):149.
8. Pramanik R, Srivastava P, Sharma A, Mehta P, **Patel A**, Bhethanabhotla S, et al. Management of head-and-neck cancer during COVID-19 crisis: A medical oncology perspective. Indian J Med Paediatr Oncol. 2020 Jan 4; 41(2):153.
9. Bhethanabhotla S, Pramanik R, Srivastava P, Mehta P, **Patel A**, Biswas B, et al. Colorectal cancer chemotherapy during COVID-19 pandemic. Indian J Med Paediatr Oncol.2020 Jan 4; 41(2):156.
10. Das CK, Mahindru S, **Patel** A, Batra A, Biswas B, Mehta P, et al. How I treat epithelial ovarian cancer during COVID-19 pandemic. Indian J Med Paediatr Oncol. 2020 Jan 4; 41(2):138.
11. Mahindru S, Das CK, **Patel A**, Mehta P, Biswas B, Batra A, et al. Cancer surgery in challenging time of COVID-19 pandemic – A pragmatic approach. Indian J Med Paediatr Oncol. 2020 Jan 4;41(2):14
12. Dabkara D, Ganguly S, Ghosh J, **Patel A**, Batra A, Das CK, et al. How We Treat Genitourinary Cancers During COVID-19 Pandemic? Asian Pac J Cancer Care. 2020 Jul 1; 5(S1):147–52.

**MUSINGS/PERSPECTIVE -**

1. **Patel A**. Bathinda to Bikaner: My experience of the “cancer train.” Cancer Res Stat Treat. 2021 Apr 1; 4(2):208.

**ABSTRACTS -**

1. Prognostic significance of “B” symptoms in pediatric T-lymphoblastic lymphoma: an analysis of 46 patients treated with BFM-90 protocol”. Authors - **Amol Patel**, Bivas Biswas, Mamta Kumari, Sameer Bakhshi. Abstract no PD-06. SIOP 2016 Scientific Programme+Index. Pediatr Blood Cancer. 2016;63(S3):S5–321.
2. Pretreatment neutrophil to lymphocyte ratio predicts event free and overall survival in patients of childhood T cell non-Hodgkin lymphoma”. Authors - **Amol Patel**, Bivas Biswas, Sameer Bakhshi, Abstract No PD-0431. SIOP 2016 Scientific Programme+Index. Pediatr Blood Cancer. 2016;63(S3):S5–321
3. **Patel A**, Biswas B, G T, A S, S B. Serum Zinc Level and Pediatric Acute Myeloid Leukemia: A Prospective Observational Study. Pediatr Blood Cancer. 2018 Nov; 65: S185. (Poster presentation – SIOP 2018 Kyoto).
4. Das CK, **Patel A**, Raj A, Gupta VG, Mehta P, Bhethanabhotla S, et al. Anti-Her2neu directed therapy in advanced gall bladder cancer: A prospective, multicenter experience from India. J Clin Oncol. 2020 May 20; 38(15\_suppl): e16682–e16682.
5. **Patel A,** Singh HP, Pandalanghat S, Kumar M, Guleria B, Mathighatta Shivarudraiah SS. Genomic architecture of gallbladder cancer: Results of a first prospective study. J Clin Oncol. 2020 May 20; 38(15\_suppl): e16628–e16628.
6. **Patel A**N, Singh HP, Nair R, Buva D. 50P Ultrasound guided screening of gallbladder cancer in healthy volunteers: A prospective study from Northern India. Ann Oncol. 2020 Sep; 31: S260.
7. Ramegowda KM, **Patel AN**, Singh HP, Kapoor A, Pandalanghat S, Mulajker DS, et al. 271P Prospective study on toxicity profile of immunotherapy in a Indian population: A real-world experience. Ann Oncol. 2022 Nov 1; 33:S1538.
8. Shivashankara MS, Viswanath S, Pandalanghat S, **Patel AN**, Guleria B, Rathore A, et al. 1662P Outcomes and prognostic factors in localized soft tissue sarcoma: Prospective observational study. Ann Oncol. 2020 Sep 1; 31:S989.

**BOOK CHAPTERS**:

1. Targeted therapy in Gallbladder cancer
2. Approach to a patient of rising jaundice

**MANUSCRIPTS UNDER PUBLICATION**:

1. Systematic review of cancer care giver burden (CSRT)
2. Rectal cancer management guidelines for Indian patients (IJMPO)
3. ERBB pathway and mechanisms of resistance (MJAFI)
4. Cisplatin 40 mg versus 100 mg RCT (JCO)
5. Real-world Lorlatinib in lung cancer (Lung cancer journal)
6. ICIs low, mg/kg and conventional dose ICIs – a century. (JCO GO)

**AWARDS** :

* Invitation from Queens University, Ontario Canada- Fellowship in Cancer care research.
* Dr Kalla Venkat Young Researcher Award ISMPO (First prize) 2022
* Dr JC Patel and BC Mehta Best paper Award (second prize) 2021
* iCMLf Preceptorship award 2020
* SIOP Scholarship award 2016
* Gujar Sainik Samman, Kedareshwar Prathisthan Pune, 2014
* Shri Brihad Bharatiya Samaj Scholarships for 1998

**MEDICAL LICENSURE**

* Maharashtra Medical Council, India

Registration (MBBS) # 2002/03/1062 (dated 05 Mar 2002)

* Medical Council of India (MCI) certificate no 10-9423 for MD (General Medicine)
* Medical Council of India (MCI) certificate no 17-25669 for DM (Medical Oncology)

**CLINICAL EXPERIENCE**

* Internship – Bytco Hospital, Nasik Municipal Corporation Hospital, Nasik, Maharashtra, India (Jan 2001- Feb 2002)
* Served in High Altitude Area in Himalayan ranges for two and half years as Medical officer in Indian Army.
* Resident in Department of Internal Medicine for three years, Armed Forces Medical College, Pune (July 2006-June 2009)
* Served as Physician for two years in Indian Army in a Desert region.
* Served as Physician at Indo-Bhutan Friendship Hospital, **Thimphu, Bhutan** for two years ( Jul 2011- Jun 2013)
* Senior Resident (Medical Oncology), Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India (July 2014-till Jun 2017)
* Classified Specialist (Medicine ) & Assistant Professor of Medical Oncology at Army Hospital Research & Referral, New Delhi ( Jul 2017- 24 Jul 2020)
* Associate Professor of Medicine & Medical Oncologist at Indian Naval Hospital Ship, Asvini, Mumbai (01 Aug 2020 – till date)

**INTERNATIONAL WORKSHOPS/CMEs/PRESENTATIONS**

* Poster presented at 48th Congress of the International Society of Paediatric Oncology, October 19-22, 2016 in **Dublin**, Ireland with title “Pretreatment neutrophil to lymphocyte ratio predicts event free and overall survival in patients of childhood T cell non-Hodgkin lymphoma”. Authors - Amol Patel, Bivas Biswas, Sameer Bakhshi.
* Poster presented at 48th Congress of the International Society of Paediatric Oncology, October 19-22, 2016 in **Dublin**, Ireland with title “Prognostic significance of “B” symptoms in pediatric T-lymphoblastic lymphoma: an analysis of 46 patients treated with BFM-90 protocol”. Authors - Amol Patel, Bivas Biswas, Mamta Kumari, Sameer Bakhshi.
* ESMO advanced course on Clinical questions in advanced prostate cancer, **Singapore** 6-7th September 2019.

**VOLUNTEER AND COMMUNITY ACTIVITIES**

* Worked as a member of National Social Service in 1997 – 1999.
* Coordinating Glivec International Patient Assistance Program (GIPAP) for CML and GIST patients at AIIMS, New Delhi

**MEMBERSHIPS**

* Indian Society of Medical & Paediatric Oncology ID: 1490
* Association of Physicians of India ID: L-15933
* European Society of Medical Oncology (ESMO) ID: 353784
* American Society of Clinical Oncology (ASCO) ID: 579378
* Indian Co-operative Oncology Network (ICON) ID:
* Science and Cost Cancer Consortium, New Delhi

**MEMBER OF ACADEMIC COMMITTEES**

* Member of Indian Council of Medical Research guidelines on Hepatocellular carcinoma
* Member of Indian Council of Medical Research guidelines on Carcinoma of Unknown Primary
* Member of international committee on Gallbladder reporting and data system **(GB-RADS**)

 **RESEARCH INTEREST AND PROJECTS**

* Value based care in low- and middle-income countries. Leading the work on approval of Pembrolizumab mg/kg in India.
* Completed study -Significance of micronutrient (Zinc) in pediatric Acute Myeloid Leukemia- an observational study (under publication).
* Completed study - Pediatric Non-Hodgkin’s lymphoma – Clinicopathological and outcome analysis of patients treated at tertiary care center of Northern India (published).
* **Ongoing research studies** -
	+ Comprehensive genomic profiling by next generation sequencing (Foundation Medicine) of Gall bladder cancers to reveal tumor-specific differences and genomic alterations: A Phase 2 single arm, multicohort trial, open label is ongoing. **(CTRI/2020/05/025147 [Registered on: 13/05/2020]**
	+ Gemcitabine-Capecitabine (GEM-CAP) in advanced and metastatic Gall bladder cancer – Role of DPYD expression: An exploratory prospective study.
	+ **Real world prospective multi-centre study of Low dose Abiraterone with meals in Indian patients (CTRI/2021/07/034740** **Registered on 09/07/2021)**
	+ BRCA and Triple negative cancer- association and ground realities of Risk reducing surgeries in Indian setting.
	+ Role of Nivolumab in relapsed, refractory patients of Hodgkin Lymphoma treated at Army Hospital (R&R), Delhi
	+ Low dose Abiraterone – Food dairies of Indian patient.
	+ Circulating tumor cells in biliary tract cancer –
	+ Losartan with standard of care in gallbladder cancer
	+ Perspectives of patients on PFS, OS and costly drugs
	+ Care giver burden analysis
	+ AFMRC – Gallbladder cancer 20,000 genes; DNA, RNA transcriptomics and Germline variant analysis.
* Future projects under consideration –
* CML social app (patients, doctors, care givers at one platform)
	+ Low dose Nivolumab in metastatic/recurrent head and neck and lung cancer.
	+ Role of High dose Methotrexate in high-risk CNS-IPI DLBCL – a retrospective prospective study
	+ Role of NGS in Triple negative breast cancer
	+ **Low dose atezolizumab plus chemotherapy** in biliary tract cancer – a phase 1 trial.
* Community based work
* Cancer awareness campaign in rural and tribal areas of Maharashtra, India
* ALK + social app

**CONFERENCES ATTENDED/LECTURES DELIVERED** –

* International conferences as speaker/faculty/moderator for sessions
* 13th International SFO conference, **14-15th December, 2018**. JDWNR Hospital, Thimphu, Bhutan
* Indian and European Regulatory and Quality Summit, **14-15th November 2019**, TOPRA, New Delhi
* 19th Annual International Conference RGCON, **7-8th February 2020.**
* National conferences as speaker and faculty
* Rajasthan Conclave 6, Desert Medicine Research Centre, Indian Council of Medical Research, **20-22th October 2018**, Jodhpur, Rajasthan
* Oncology Forum, Annual meeting **8-9th December 2018**, Delhi
* Year in Review Breast Cancer **19-20th January 2019**, Mumbai, Maharashtra
* Hematology update year in review 2018, **15-16 February 2019**, New Delhi
* 4th Molecular Oncology Society conference, **16-17 February 2019**, New Delhi
* Oncovision, AFOG **23-24 February 2019** (Organizing Committee member), A special Survivor Meet was organized for around 100 cancer patient survivors.
* 40th ICON conference, **29-31st March 2019**, Kolkata, West Bengal
* MAX Cancer congress, **17-18th August 2019,** New Delhi
* 41st ICON conference, **13th September 2019**, Ahmedabad, Gujrat. (Speaker- Low dose Abiraterone)
* Women’s Cancer Conclave, **14th September 2019**, Mumbai, Maharashtra (speaker)
* 4th Best of WCLC 2019, **22th** **September 2019**, New Delhi (panel moderation)
* Metastatic breast cancer Summit (Oncology Forum), Molecular pathways – a new hope, **19th October 2019**, New Delhi (speaker)
* Optimizing outcomes in ALK rearranged mNSCLC, Preceptorship on mNSCLC, **18th January 2020**, RGCI, Delhi (speaker)
* **Webinars** during this pandemic - 25